Physician profile
Fitzclaud Grant
NPI 1194893990
$3,550.55
in general payments reported to CMS, 2019-2025
23 companies · $395 in 2025
The $395 reported for 2025 was more than what 75% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $677 · 2020: $517 · 2021: $422 · 2022: $352 · 2023: $460 · 2024: $728 · 2025: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,582.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $889.14 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Arbor Pharmaceuticals, INC. | $322.47 | 2019-2021 | |
| Glaxosmithkline, LLC. | $289.82 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $268.13 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $229.44 | 2019-2020 | |
| Novo Nordisk INC | $225.80 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.89 | 2020-2025 | Jardiance, Synjardy |
| Exact Sciences Corporation | $214.49 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $197.03 | 2023-2024 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $150.51 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $95.84 | 2022 | |
| Abbvie INC. | $89.28 | 2021-2025 | |
| Astellas Pharma US INC | $53.26 | 2024 | Veozah |
| Allergan, INC. | $50.83 | 2019-2020 | |
| Azurity Pharmaceuticals, INC. | $43.43 | 2024-2025 | Edarbi |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $42.71 | 2019-2022 | |
| Esperion Therapeutics, INC. | $40.88 | 2020-2021 | |
| Amgen INC. | $29.39 | 2019 | |
| Opko Pharmaceuticals, LLC | $24.38 | 2024 | Rayaldee |
| Renalytix Ai, INC. | $21.52 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Avanir Pharmaceuticals, INC. | $16.21 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fitzclaud Grant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.